Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Gilbert, AZ
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Not yet accepting
SUCCESSOR-1
Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- CELMoD
- Randomization
- Phase 3
Accepting patients
STOMP
Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma.
- CELMoD
- SINE
- Phase 1/2
- Has results
Accepting patients
MagnetisMM-7
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)
- Bispecific Antibody
- GPRC5D
- Phase 3
Accepting patients
iMMagine-3
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- Randomization
- Phase 3
Accepting patients
Belantamab Mafodotin or Lenalidomide Maintenance
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
- Immunomodulatory Drug
- BCMA
- Maintenance
- Randomization
- Phase 2
Accepting patients
OPN-662
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
- BET Inhibitor
- Phase 1
Accepting patients
Cord Blood Units for Neutrophil Recovery
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
- Cord Blood
- Observational Trial